What is ALVO stock price today?

ALVO (Alvotech) stock is trading at $3.47 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALVO stock going up or down today?

ALVO stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALVO stock now?

The decision to buy ALVO depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALVO a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALVO based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALVO stock overvalued or undervalued?

ALVO currently trades at a P/E ratio of 15.09 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if ALVO is fairly priced.

What is ALVO's P/E ratio?

ALVO has a price-to-earnings (P/E) ratio of 15.09, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ALVO's market cap?

ALVO (Alvotech) has a market capitalization of $1.08 billion, making it a small-cap stock.

What is ALVO's price to book ratio?

Price-to-book ratio for ALVO is available on our dashboard along with other valuation metrics.

Does ALVO pay dividends?

ALVO does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALVO's dividend yield?

ALVO does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALVO stock a good long-term investment?

ALVO's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALVO's revenue growth rate?

ALVO has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ALVO is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in ALVO?

Key risks for ALVO include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALVO compare to its competitors?

Compare ALVO to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALVO's performance and positioning.

What is ALVO's stock price target for 2026?

Our AI model provides price targets for ALVO based on fundamental analysis: Bull case $4.51 (+30%), Base case $3.99 (+15%), Bear case $3.12 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALVO?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALVO. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALVO's next earnings report?

ALVO reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALVO - Alvotech

NYSE * Health Care * Pharmaceuticals

$3.47

$-0.07 (-1.98%)

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

ALVO Key Statistics

Market Cap

$1.08B

P/E Ratio

15.09

EPS

$0.23

Revenue Growth

+0.1%

Profit Margin

0.1%

Employees

1,012

How ALVO Compares to Peers

ALVO has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

ALVO has the highest profit margins in Pharmaceuticals

ALVO is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
ALVO(This stock)	$1.08B	15.1	0%	0.1%	-
AMZNAmazon Com	$2.23T	29.0	0%	0.1%	vs AMZN

Alvotech Company Information

Headquarters: Luxembourg
Website: www.alvotech.com
Sector: Health Care
Industry: Pharmaceuticals

About Alvotech

ALVO Key Statistics

How ALVO Compares to Peers

Alvotech Company Information

Upcoming Events for ALVO